Clinical trials: Alzheimers Disease Prevention
Alzheimer Disease
Combined Aerobic Exercise and Cognitive Training in Seniors With Genetic Susceptibility for Alzheimer's Disease
The study aims to investigate the effect of a long-term combined aerobic exercise and cognitive training program on cognitive function, daily function, psychosocial status, and neural plasticity in seniors with genetic…
- Trial name
- NCT05163067
- Testing
- Combined aerobic exercise and cognitive training program
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xuanwu Hospital, Beijing
Subjective Cognitive Decline (SCD)
PENSA+: Extended Follow-up of a Multimodal Lifestyle Intervention to Prevent Cognitive Decline in APOE-ε4 Carriers
PENSA+ is a 5-year follow-up study of participants who previously completed the PENSA clinical trial (NCT03978052), which evaluated an intensive multimodal lifestyle intervention, with or without epigallocatechin gallate (EGCG)…
- Trial name
- PENSA+ (NCT07730671)
- Where
- Spain
- Volunteers
- 121 people
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Alzheimer Disease
Epidemiology and Biomarker Study in Alzheimer's Disease
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
- Trial name
- ANCHOR-AD (NCT07142954)
- Testing
- P-tau217 Test
- Where
- 4 sites in United States, Japan
- Volunteers
- 3,400 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Dementia
The Retain Your Brain Health Study (RetainYourBrain.com)
The goal of this clinical trial is to test a cell phone-based online program that provides Alzheimer's risk assessments and memory tests over a 6-month period.
- Conditions
- Alzheimer Disease, Dementia, Healthy Participants, Brain Health
- Trial name
- NCT06027320
- Testing
- Brain Health Education, Alzheimer Disease Education
- Where
- United States
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Retain Health, Inc
Alzheimer Disease
Nutrition Interventions for Cognitive Enhancement
By doing this study, researchers hope to learn how the Mediterranean and low-fat eating patterns affect memory, brain volume, brain antioxidant status and cardio-metabolic biomarkers, such as blood pressure and blood glucose, in…
- Trial name
- NICE (NCT03841539)
- Testing
- Mediterranean Diet, Study Supplement, Low-fat Diet
- Where
- United States
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Alzheimers Disease, Dementia
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation.
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT05552157)
- Testing
- Remternetug (SC)
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Depression
Personalized Prevention of Depression in Primary Care
The main goal is to design, develop and evaluate a personalized intervention to prevent the onset of depression based on Information and Communications Technology (ICTs), risk predictive algorithms and decision support systems…
- Trial name
- NCT03990792
- Testing
- e-predictD intervention, Brief psychoeducational intervention
- Where
- 6 sites in Spain
- Volunteers
- 663 people
- Sponsor
- The Mediterranean Institute for the Advance of Biotechnology and Health Research
Depression, Anxiety Disorders
The PredictPlusPrevent Study
Objective: To design, develop, and evaluate a personalized intervention for the universal prevention of depression and anxiety in the general population based on risk algorithms, ICTs, and decision support systems (DSS).
- Trial name
- NCT06351800
- Testing
- Predictplusprevent intervention, Psychoeducational intervention
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- The Mediterranean Institute for the Advance of Biotechnology and Health Research
Alzheimer Disease, Dementia
Financial Incentives and Recruitment to the APT Webstudy
This single-blind, three-arm, randomized, controlled trial will assess the impact of messages and financial incentives on the enrollment of demographically diverse individuals to the Alzheimer Prevention Trials (APT) Webstudy.
- Conditions
- Alzheimer Disease, Dementia, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- FIND-AD (NCT06033066)
- Testing
- Financial Incentives, Message
- Where
- United States
- Volunteers
- 44,844 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD)
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
The study will explore the impact of photobiomodulation (PBM), pulsating at frequencies of red (660nm) and near-infrared (810nm)(NIR), concurrent with a ketogenic dietary protocol (serum ketones @ .5 - 2.0 mmol/L) to mediate…
- Conditions
- Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
- Trial name
- NCT03859245
- Testing
- Photobiomodulation, Ketogenic diet
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Cognition Disorders
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer…
- Trial name
- A4 (NCT02008357)
- Testing
- Solanezumab
- Where
- 68 sites in United States, Australia and 2 more
- Volunteers
- 1,169 people
- Sponsor
- Eli Lilly and Company
Wisconsin Alzheimer's Disease Research Center, Wisconsin Registry for Alzheimer's Prevention
Speech Pattern Evaluation and Analysis for Knowledge of AD
The goal of this observational study is to validate changes in speech as a measure of cognition in individuals at increased risk of Alzheimer's disease and related dementias (ADRD).
- Trial name
- SPEAK-AD (NCT06230783)
- Testing
- TalkTracker
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Dementia, Alzheimer's Disease
Ginkgo Biloba Prevention Trial in Older Individuals
This study will determine the effect of 240mg/day Ginkgo biloba in decreasing the incidence of dementia and specifically Alzheimer's disease (AD), slowing cognitive decline and functional disability, reducing incidence of…
- Trial name
- NCT00010803
- Testing
- Ginkgo biloba
- Where
- 5 sites in United States
- Volunteers
- 3,069 people, healthy volunteers welcome
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Age Related Cognitive Decline, Alzheimer's Disease
n-3 PUFA for Vascular Cognitive Aging
Brain scans can help identify changes that appear to increase risk for cognitive decline and dementia. Some of these brain changes are thought to reflect actual damage to the small blood vessels that support normal brain…
- Conditions
- Age Related Cognitive Decline, Alzheimer's Disease, Vascular Dementia, Endothelial Dysfunction
- Trial name
- NCT01953705
- Testing
- Omega 3 PUFA
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Alzheimer Disease, Cognitive Decline
Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal Intervention
Alzheimer's disease (AD) neuropathology is characterized by deposits of insoluble amyloid β-peptide (Aβ) in extracellular plaques and aggregated tau protein, which is found largely in the intracellular neurofibrillary tangles.
- Trial name
- (PENSA) (NCT03978052)
- Testing
- EGCG, Healthy lifestyle recommendations, Multimodal lifestyle intervention
- Where
- 2 sites in Spain
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Parc de Salut Mar
Aging, Alzheimer Disease
The Nightlight Falls Prevention Study
This project will test the effectiveness of a novel intervention consisting of unobtrusive, low-intensity, horizontal and vertical lights that outline the bathroom or entry way doorframe in residents' rooms and provide visual…
- Conditions
- Aging, Alzheimer Disease, Dementia Alzheimers, Dementia of Alzheimer Type
- Trial name
- NCT05973448
- Testing
- Novel Lighting Condition, Control Lighting Condition
- Where
- United States
- Volunteers
- 335 people
- Sponsor
- University of North Carolina, Chapel Hill
Alzheimer Disease, Dementia
Follow-up Study of the Alzheimer's Disease Anti-Inflammatory Prevention Trial
The Alzheimer's Disease Anti-inflammatory Prevention Trial - Follow-up Study (ADAPT-FS) will continue observations of the declared primary outcomes of the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) in the…
- Trial name
- ADAPT-FS (NCT01417130)
- Where
- 6 sites in United States
- Volunteers
- 1,650 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Dementia
Handwriting as an Objective Tool to Support the Identification of People With Alzheimer's Disease
Alzheimer's disease (AD) is the most common of dementia, and has associated cognitive and motor disorders, with consequences on daily activities, including handwriting.
- Trial name
- HAD (NCT06483438)
- Where
- 3 sites in Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Évora
Alzheimers Disease
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in…
- Trial name
- GS1 (NCT02565511)
- Testing
- CAD106 Immunotherapy, CNP520, Alum
- Where
- 129 sites in United States, Australia and 8 more
- Volunteers
- 480 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Effects of Simvastatin on Biomarkers
A year-long randomized, double-blind, placebo-controlled trial of simvastatin to see if it produces beneficial changes in cerebral spinal fluid proteins associated with Alzheimer's disease.
- Trial name
- SimBio (NCT01142336)
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Washington